Home

Effectiveness Trial Of Attention Shaping For Schizophrenia

Steven M Silverstein, Associate Professor
Univ Of Med/dent Nj-r W Johnson Med Sch Robert Wood Johnson Medical Sch Piscataway, Nj 088548021

Grant 5R01MH074650-02 from National Institute Of Mental Health, IRG: APDA

Abstract: Among people with schizophrenia, attentional impairment is a major barrier to being able to engage in, and learn new skills in, psychosocial skills training interventions. Therefore, developing methods to promote attentiveness and learning during skills training is an important step in improving treatment outcomes. Prior case reports, one controlled study, and data from an ongoing R21 application indicate that attention shaping procedures (ASP) are highly effective methods to achieve these goals. ASP is a manualized, behavioral intervention that involves individualized goal-setting, and standardized observational rating, prompting, and reinforcement procedures to assist patients in increasing the duration and quality of their attentiveness in psychosocial interventions. To date, studies of ASP have been limited in their outcome evaluations to in- group attentiveness and learning of group material. Other cognitive outcomes, generalizability, functional outcomes and durability of gains have not been studied. This proposal, therefore, describes a controlled effectiveness study of ASP that would comprehensively assess relevant outcomes, generalizability, functional skills related to those taught in the intervention and maintenance of the gains over six months. ASP will be integrated within a standard form of social skills training [UCLA Basic Conversation Skills Module (BCS)], and compared to a BCS-alone condition. Specific aims of the study involve examinations of 1) the generalizability of ASP s effects to relevant domains of non-study-group attentiveness, and standardized measures of neurocognition; 2) functional outcomes involving social skills, as assessed through self-report, other-report, interview, and role-play based measures; and 3) the durability of ASP-associated gains, by conducting a 6-month follow-up assessment on all subjects. Statistical analyses will involve time-series and growth curve models that make use of daily in-group performance data to model treatment response. These data, plus more traditional analyses will determine whether, and to what extent, ASP confers advantages in attention, and learning and/or performance of behavioral skills to patients who receive it. The long-term objective of this project is to demonstrate that ASP can narrow the gap between the existence of potentially effective psychosocial interventions (such as skills training) and patients who, at present, cannot benefit from them due to attentional difficulties.

Keywords: attention, behavior modification, behavior therapy, human therapy evaluation, psychosocial rehabilitation, schizophrenia, clinical trial, outcomes research, reinforcer, behavioral /social science research tag, clinical research, human subject, medical rehabilitation related tag, neuropsychological test, patient oriented research

Project start date: 2006-09-14

Project end date: 2011-07-31

5R01MH074650-02 (2007): $455946


Sponsored Links Lab Supply Mall http://www.labsupplymall.com

Invitrogen Human Cot-1 DNA Cat# 15279-011
Block non-specific hybridization in microarray screening. $155, $120
GR Safe Nucleic Acid Stain
Excellent Alternative to Ethidium Bromide: Safety, Sensitivity, Stability. $78, $58
New Invitrogen UltraPure Agarose 500g
UltraPure Agarose resolves DNA and RNA fragments from 100 bp to >30 kb. $432, $350
Qiagen QIAprep Spin Miniprep Kit (250), Cat # 27106
For purification of up to 20 ug molecular biology grade plasmid DNA. $328, $285
Qiagen EndoFree Plasmid Maxi Kit (10), Cat # 12362
For purification of up to 500 ug advanced transfection grade plasmid or cosmid DNA. $266, $210
Qiagen QIAEX II Gel Extraction Kit (150), Cat # 20021
For batch purification of DNA fragments (40 bp to 50 kb) from agarose gels and from solutions. $137, $105
Amersham ECL Plus Western Blotting Detection Reagents, Cat # RPN2132
Superior sensitivity.. $230, $55
Invitrogen Life Technology Gibo Lipofectamine 2000, 1.5 ml, Cat 11668-019
Unsurpassed Results for DNA and siRNA Transfections. $399, $350
Qiagen Ni-NTA Agarose beads 25 ml Cat # 30210
For purification of 6xHis-tagged proteins by gravity-flow chromatography. $225, $180
Qiagen RNeasy Mini Kit (50), Cat # 74104
For purification of up to 100 ug total RNA from animal cells or tissues, yeast, or bacteria. $219, $170

Effectiveness Trial Of Attention Shaping For Schizophrenia

Steven M Silverstein, Associate Professor
Psychiatryuniv Of Med/dent Nj-r W Johnson Med Sch

Grant 5R01MH074650-03 from National Institute Of Mental Health, IRG: APDA

Abstract: Among people with schizophrenia, attentional impairment is a major barrier to being able to engage in, and learn new skills in, psychosocial skills training interventions. Therefore, developing methods to promote attentiveness and learning during skills training is an important step in improving treatment outcomes. Prior case reports, one controlled study, and data from an ongoing R21 application indicate that attention shaping procedures (ASP) are highly effective methods to achieve these goals. ASP is a manualized, behavioral intervention that involves individualized goal-setting, and standardized observational rating, prompting, and reinforcement procedures to assist patients in increasing the duration and quality of their attentiveness in psychosocial interventions. To date, studies of ASP have been limited in their outcome evaluations to in- group attentiveness and learning of group material. Other cognitive outcomes, generalizability, functional outcomes and durability of gains have not been studied. This proposal, therefore, describes a controlled effectiveness study of ASP that would comprehensively assess relevant outcomes, generalizability, functional skills related to those taught in the intervention and maintenance of the gains over six months. ASP will be integrated within a standard form of social skills training [UCLA Basic Conversation Skills Module (BCS)], and compared to a BCS-alone condition. Specific aims of the study involve examinations of 1) the generalizability of ASP´s effects to relevant domains of non-study-group attentiveness, and standardized measures of neurocognition; 2) functional outcomes involving social skills, as assessed through self-report, other-report, interview, and role-play based measures; and 3) the durability of ASP-associated gains, by conducting a 6-month follow-up assessment on all subjects. Statistical analyses will involve time-series and growth curve models that make use of daily in-group performance data to model treatment response. These data, plus more traditional analyses will determine whether, and to what extent, ASP confers advantages in attention, and learning and/or performance of behavioral skills to patients who receive it. The long-term objective of this project is to demonstrate that ASP can narrow the gap between the existence of potentially effective psychosocial interventions (such as skills training) and patients who, at present, cannot benefit from them due to attentional difficulties

Keywords: attention, behavior modification, behavior therapy, human therapy evaluation, psychosocial rehabilitation, schizophrenia clinical trial, outcomes research, reinforcer behavioral /social science research tag, clinical research, human subject, medical rehabilitation related tag, neuropsychological test, patient oriented research

Project start date: 2006-09-14

Project end date: 2011-07-31



Grants awarded to Steven M Silverstein

3/5-Cognitive Neuroscience Task Reliability & Clinical Applications Consortium

Steven M Silverstein
Psychiatryuniv Of Med/dent Nj-r W Johnson Med Sch

Grant 1R01MH084828-01 from National Institute Of Mental Health, IRG: ZMH1

Abstract: Over the past decade there has been a growing awareness of the disabling effects of impaired cognition in individuals with schizophrenia. Along with this new awareness has come an increasing emphasis on the importance of developing new treatments that may positively impact these cognitive deficits. During this same period, the cognitive neuroscience field has seen an explosion of technical advances and new knowledge regarding the neural basis of cognition. Sadly, the translation and application of this cutting edge knowledge and paradigm development to new drug development in schizophrenia has lagged significantly behind overall progress in cognitive neuroscience, in large part due to the lack of data on the measurement properties of tasks used in cognitive neuroscience. This concern spawned the Cognitive Neuroscience Research To Improve Cognition in Schizophrenia (CNTRICS) initiative, which conducted a series of conferences designed to develop consensus on the constructs and paradigms from cognitive neuroscience that are ripe for translation, and the validation and psychometric goals when translating such tasks for use in clinical trials contexts. The current application is a logical and needed extension of the CNTRICS initiative that will begin the translation process for paradigms designed to assess four of the constructs identified as being ripe for translation in the first CNTRICS meeting. We have brought together a collaborative "translation" team that represents significant expertise from the many fields necessary for the success of this endeavor, including both basic and clinical cognitive neuroscientists, psychometricians, and clinical trials specialists. We have chosen to focus on four constructs that span both early (gain control and visual integration in perception) and higher-level (goal maintenance, relational encoding and retrieval) components of human cognitive processing. By examining multiple mechanisms, we will be able to establish the generality of the translational approach we propose across different levels and types of cognitive mechanisms. Specific Aim 1 is to validate (in both individuals with schizophrenia and comparison participants) optimized versions of the paradigms that assess our four constructs of interest, as well as to examine the relationship of task performance to clinical and functional outcomes in schizophrenia. By optimization, we mean examining modifications on already validated paradigms that are designed to 1) minimize task length; 2) simplify task administration across multiple sites; 3) maximize sensitivity and selectivity in assessing the specific cognitive mechanisms of interest; and 4) enhance reliability and minimize floor and ceiling effects. By validation, we mean ensuring that such optimizations designed to enhance the psychometric properties of the task do not alter its construct validity. Specific Aim 2 will be to assess and optimize test-retest reliability and practice effects for the task versions validated in Specific Aim 1. PROJECT NARRATIVE This project has high relevance for public health by significantly improving our ability to translate paradigms developed into the basic cognitive neuroscience literature for use in clinical trials aimed at improving cognition in schizophrenia. Cognitive deficits in schizophrenia are a major predictor of functional outcome in this debilitating illness. Thus, we need to improve our methods for detecting and enhancing cognitive function in schizophrenia in order to help individuals with this illness lead more productive and fulfilling lives

Project start date: 2008-09-30

Project end date: 2011-05-31


Shaping Attention In Treatment-Refractory Schizophrenia

Steven M Silverstein, Associate Professor
University Of Illinois At Chicago 310 Aob, M/c 672 Chicago, Il 60612

Grant 5R21MH063967-04 from National Institute Of Mental Health, IRG: ZRG1

Abstract: Despite pharmacologic treatment advances, there are many treatment-refractory schizophrenia patients remaining in state hospitals. Many of these patients are sufficiently cognitively impaired that they benefit little from psychosocial interventions and have little chance of returning to the community without the introduction of novel cognition-enhancing interventions. Moreover, many patients who have been discharged from state hospitals in the wake of recent census reductions also have attentional problems that preclude their ability to fully engage in, and benefit from, psychosocial interventions. Such patients can be considered at heightened risk for relapse and rehospitalization as long as their limited ability to benefit from treatment remains undressed. Compounding this problem is the inability of current cognitive rehabilitation interventions to improve attentional functioning in schizophrenia patients with the most severe attentional problems. For such patients, behaviorally oriented attention shaping procedures have demonstrated effectiveness in several small-scale studies. However, the lack of a user-friendly, standardized format for the delivery of this intervention has led to its almost complete nonuse outside of academic research centers. Therefore, the proposed study seeks to draw on the expertise of those investigators who have pioneered the use of shaping techniques to improve attention in treatment-refractory schizophrenia patients, in order to integrate these techniques into a standardized, manualized treatment intervention, along with an accompanying training videotape and therapist fidelity evaluation measure. The proposed project would develop this standardized treatment delivery format, and then refine it through a series of pilot treatment groups at three sites Weill Medical College of Cornell University, Lincoln Regional Center, and Hawaii State Hospital. In addition, data would be collected and pooled regarding treatment-related changes in attentional functioning, skill acquisition in groups, and symptomatology. The expected results of this project include 1) the development of a user-friendly set of materials to facilitate dissemination of the attention shaping intervention to real-world settings; 2) the collection of preliminary data on its effectiveness; and 3) the generation of estimates of power and subject variability which can serve as the foundation from which to design a large-scale controlled treatment study.

Keywords: attention, computer assisted patient care, computer program /software, human therapy evaluation, method development, neuropsychology, psychotherapy, schizophrenia, computer human interaction, handbook, information dissemination, learning, outcomes research, reinforcer, videotape /videodisc, behavioral /social science research tag, clinical research, data collection methodology /evaluation, human subject, interview, mental disorder diagnosis, patient oriented research, psychological test

Project start date: 2003-02-14

Project end date: 2007-01-31

5R21MH063967-04 (2005): $211187


5R21MH063967-03 (2004): $172878

Shaping Attention In Treatment--Refractory Schizophrenia

Steven M Silverstein, Associate Professor
Weill Medical College Of Cornell Univ 1300 York Avenue New York, Ny 10021

Grant 1R21MH063967-01A2 from National Institute Of Mental Health, IRG: ZRG1

Abstract: Despite pharmacologic treatment advances, there are many treatment-refractory schizophrenia patients remaining in state hospitals. Many of these patients are sufficiently cognitively impaired that they benefit little from psychosocial interventions and have little chance of returning to the community without the introduction of novel cognition-enhancing interventions. Moreover, many patients who have been discharged from state hospitals in the wake of recent census reductions also have attentional problems that preclude their ability to fully engage in, and benefit from, psychosocial interventions. Such patients can be considered at heightened risk for relapse and rehospitalization as long as their limited ability to benefit from treatment remains undressed. Compounding this problem is the inability of current cognitive rehabilitation interventions to improve attentional functioning in schizophrenia patients with the most severe attentional problems. For such patients, behaviorally oriented attention shaping procedures have demonstrated effectiveness in several small-scale studies. However, the lack of a user-friendly, standardized format for the delivery of this intervention has led to its almost complete nonuse outside of academic research centers. Therefore, the proposed study seeks to draw on the expertise of those investigators who have pioneered the use of shaping techniques to improve attention in treatment-refractory schizophrenia patients, in order to integrate these techniques into a standardized, manualized treatment intervention, along with an accompanying training videotape and therapist fidelity evaluation measure. The proposed project would develop this standardized treatment delivery format, and then refine it through a series of pilot treatment groups at three sites Weill Medical College of Cornell University, Lincoln Regional Center, and Hawaii State Hospital. In addition, data would be collected and pooled regarding treatment-related changes in attentional functioning, skill acquisition in groups, and symptomatology. The expected results of this project include 1) the development of a user-friendly set of materials to facilitate dissemination of the attention shaping intervention to real-world settings; 2) the collection of preliminary data on its effectiveness; and 3) the generation of estimates of power and subject variability which can serve as the foundation from which to design a large-scale controlled treatment study.

Keywords: attention, computer assisted patient care, computer program /software, human therapy evaluation, method development, neuropsychology, psychotherapy, schizophrenia, computer human interaction, handbook, information dissemination, learning, outcomes research, reinforcer, videotape /videodisc, behavioral /social science research tag, clinical research, data collection methodology /evaluation, human subject, interview, mental disorder diagnosis, patient oriented research, psychological test

Project start date: 2003-02-14

Project end date: 2003-09-26

1R21MH063967-01A2 (2003): $141280


Effectiveness Trial Of Attention Shaping For Schizophrenia

Steven M Silverstein, Associate Professor
Univ Of Med/dent Nj-r W Johnson Med Sch Robert Wood Johnson Medical Sch Piscataway, Nj 088548021

Grant 1R01MH074650-01A1 from National Institute Of Mental Health, IRG: APDA

Abstract: Among people with schizophrenia, attentional impairment is a major barrier to being able to engage in, and learn new skills in, psychosocial skills training interventions. Therefore, developing methods to promote attentiveness and learning during skills training is an important step in improving treatment outcomes. Prior case reports, one controlled study, and data from an ongoing R21 application indicate that attention shaping procedures (ASP) are highly effective methods to achieve these goals. ASP is a manualized, behavioral intervention that involves individualized goal-setting, and standardized observational rating, prompting, and reinforcement procedures to assist patients in increasing the duration and quality of their attentiveness in psychosocial interventions. To date, studies of ASP have been limited in their outcome evaluations to in- group attentiveness and learning of group material. Other cognitive outcomes, generalizability, functional outcomes and durability of gains have not been studied. This proposal, therefore, describes a controlled effectiveness study of ASP that would comprehensively assess relevant outcomes, generalizability, functional skills related to those taught in the intervention and maintenance of the gains over six months. ASP will be integrated within a standard form of social skills training [UCLA Basic Conversation Skills Module (BCS)], and compared to a BCS-alone condition. Specific aims of the study involve examinations of 1) the generalizability of ASP s effects to relevant domains of non-study-group attentiveness, and standardized measures of neurocognition; 2) functional outcomes involving social skills, as assessed through self-report, other-report, interview, and role-play based measures; and 3) the durability of ASP-associated gains, by conducting a 6-month follow-up assessment on all subjects. Statistical analyses will involve time-series and growth curve models that make use of daily in-group performance data to model treatment response. These data, plus more traditional analyses will determine whether, and to what extent, ASP confers advantages in attention, and learning and/or performance of behavioral skills to patients who receive it. The long-term objective of this project is to demonstrate that ASP can narrow the gap between the existence of potentially effective psychosocial interventions (such as skills training) and patients who, at present, cannot benefit from them due to attentional difficulties.

Keywords: attention, behavior modification, behavior therapy, human therapy evaluation, psychosocial rehabilitation, schizophrenia, clinical trial, outcomes research, reinforcer, behavioral /social science research tag, clinical research, human subject, medical rehabilitation related tag, neuropsychological test, patient oriented research

Project start date: 2006-09-14

Project end date: 2011-07-31

1R01MH074650-01A1 (2006): $446350



Related Publications

1:

Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain.

Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS; Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group.

J Cataract Refract Surg. 2009 Jan;35(1):26-34.

PMID: 19101421 [PubMed - in process]

2:

Social cognition as a mediator of cognition and outcome among deaf and hearing people with schizophrenia.

Horton HK, Silverstein SM.

Schizophr Res. 2008 Oct;105(1-3):125-37. Epub 2008 Aug 22.

PMID: 18722092 [PubMed - indexed for MEDLINE]

3:

Visual perception and its impairment in schizophrenia.

Butler PD, Silverstein SM, Dakin SC.

Biol Psychiatry. 2008 Jul 1;64(1):40-7.

PMID: 18549875 [PubMed - indexed for MEDLINE]

4:

Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change.

Silverstein SM.

Schizophr Bull. 2008 Jul;34(4):645-55. Epub 2008 May 8. Review.

PMID: 18468987 [PubMed - indexed for MEDLINE]

5:

A scientific agenda for the concept of recovery as it applies to schizophrenia.

Silverstein SM, Bellack AS.

Clin Psychol Rev. 2008 Oct;28(7):1108-24. Epub 2008 Mar 18.

PMID: 18420322 [PubMed - in process]

6:

Resting electroencephalogram asymmetry and posttraumatic stress disorder.

Shankman SA, Silverstein SM, Williams LM, Hopkinson PJ, Kemp AH, Felmingham KL, Bryant RA, McFarlane A, Clark CR.

J Trauma Stress. 2008 Apr;21(2):190-8.

PMID: 18404640 [PubMed - indexed for MEDLINE]

7:

Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia.

Silverstein SM, Spaulding WD, Menditto AA, Savitz A, Liberman RP, Berten S, Starobin H.

Schizophr Bull. 2009 Jan;35(1):222-32. Epub 2008 Jan 22.

PMID: 18212327 [PubMed - in process]

8:

Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities.

Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, Kring AM, Park S, Silverstein SM, Heinssen R.

Schizophr Bull. 2008 Nov;34(6):1211-20. Epub 2008 Jan 8.

PMID: 18184635 [PubMed - in process]

9:

Development and validation of a World-Wide-Web-based neurocognitive assessment battery: WebNeuro.

Silverstein SM, Berten S, Olson P, Paul R, Willams LM, Cooper N, Gordon E.

Behav Res Methods. 2007 Nov;39(4):940-9.

PMID: 18183911 [PubMed - indexed for MEDLINE]

10:

Cognition and functional outcome among deaf and hearing people with schizophrenia.

Horton HK, Silverstein SM.

Schizophr Res. 2007 Aug;94(1-3):187-96. Epub 2007 Jun 7.

PMID: 17560083 [PubMed - indexed for MEDLINE]

11:

Theory of mind and perceptual context-processing in schizophrenia.

Uhlhaas PJ, Phillips WA, Schenkel LS, Silverstein SM.

Cognit Neuropsychiatry. 2006 Jul;11(4):416-36.

PMID: 17354079 [PubMed - indexed for MEDLINE]

12:

Perceptual grouping in disorganized schizophrenia.

Uhlhaas PJ, Phillips WA, Mitchell G, Silverstein SM.

Psychiatry Res. 2006 Dec 7;145(2-3):105-17. Epub 2006 Nov 1.

PMID: 17081620 [PubMed - indexed for MEDLINE]

13:

Comparing bimatoprost and travoprost in black Americans.

Noecker RJ, Earl ML, Mundorf TK, Silverstein SM, Phillips MP.

Curr Med Res Opin. 2006 Nov;22(11):2175-80.

PMID: 17076978 [PubMed - indexed for MEDLINE]

14:

A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma.

Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD.

Adv Ther. 2006 May-Jun;23(3):385-94.

PMID: 16912020 [PubMed - indexed for MEDLINE]

15:

Learning potential as a predictor of readiness for psychosocial rehabilitation in schizophrenia.

Fiszdon JM, McClough JF, Silverstein SM, Bell MD, Jaramillo JR, Smith TE.

Psychiatry Res. 2006 Aug 30;143(2-3):159-66. Epub 2006 Jul 24.

PMID: 16860881 [PubMed - indexed for MEDLINE]

16:

Cognitive functioning and social problem-solving skills in schizophrenia.

Hatashita-Wong M, Smith TE, Silverstein SM, Hull JW, Willson DF.

Cognit Neuropsychiatry. 2002 May;7(2):81-95.

PMID: 16571529 [PubMed]

17:

Effects of stimulus structure and target-distracter similarity on the development of visual memory representations in schizophrenia.

Silverstein SM, Bakshi S, Nuernberger S, Carpinello K, Wilkniss S.

Cognit Neuropsychiatry. 2005 Jun;10(3):215-29.

PMID: 16571460 [PubMed]

18:

Reduced top-down influences in contour detection in schizophrenia.

Silverstein SM, Hatashita-Wong M, Schenkel LS, Wilkniss S, Kovács I, Fehér A, Smith T, Goicochea C, Uhlhaas P, Carpiniello K, Savitz A.

Cognit Neuropsychiatry. 2006 Mar;11(2):112-32.

PMID: 16537237 [PubMed - indexed for MEDLINE]

19:

Perceptual organization in schizophrenia spectrum disorders: empirical research and theoretical implications.

Uhlhaas PJ, Silverstein SM.

Psychol Bull. 2005 Jul;131(4):618-32. Review.

PMID: 16060805 [PubMed - indexed for MEDLINE]

20:

Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients.

Silverstein SM, Hatashita-Wong M, Solak BA, Uhlhaas P, Landa Y, Wilkniss SM, Goicochea C, Carpiniello K, Schenkel LS, Savitz A, Smith TE.

Psychol Med. 2005 Jun;35(6):829-37.

PMID: 15997603 [PubMed - indexed for MEDLINE]